Clinical Gynecologic Oncology Chase Dana M., Wong Siu-Fun, Wenzel Lari B., Monk Bradley J., 20 - Palliative Care and Quality of Life [Book Chapter] 2018
Publications
Journal of clinical oncology Konstantinopoulos Panagiotis A, Paule Ines, Sufliarsky Jozef, Hinson Patsy, Zuradelli Monica, Wang Craig, Su Fei, Miller Michelle, Matulonis Ursula A, González-Martín Antonio, Grisham Rachel N, Kim Jae Weon, Freyer Gilles, Lee Jung Yun, Gaba Lydia, Colombo Nicoletta, Cibula David, Wu Xiaohua, Sehouli Jalid, Cruz Felipe, Lorusso Domenica, Monk Bradley J, Nyvang Gitte-Bettina, Friedlander Michael, Marth Christian, Van Nieuwenhuysen Els, Malik Rozita, Glasspool Rosalind, Marmé Frederik, Leary Alexandra, Cortés-Salgado Alfonso, Zamagni Claudio, Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation, p. JCO2500225 2025
Journal of clinical oncology Banerjee Susana N, Oaknin Ana, Van Nieuwenhuysen Els, Aghajanian Carol, D'Hondt Véronique, Monk Bradley J, Clamp Andrew, Prendergast Emily, Rodrigues Manuel, Ring Kari, Colombo Nicoletta, Holloway Robert W, Thaker Premal H, Chon Hye Sook, Gourley Charlie, Santin Alessandro D, Youssoufian Hagop, Gennigens Christine, Newman Gregg, Salinas Erin, Van Gorp Toon, Moore Kathleen N, Lustgarten Stephanie, O'Malley David M, Grisham Rachel N, , Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201, p. JCO2500112 2025
Gynecologic oncology Chan John K., McHale Michael T., Tewari Krishnansu, Monk Bradley J., Herzog Thomas J., Coleman Robert L., Richardson Michael T., Salani Ritu, Francoeur Alex A., Kapp Daniel S., Optimizing therapy for cervical cancers – Translating trial data into clinical decision-making 199, p. 47 - 50 2025
The Lancet (British edition) Olawaiye Alexander B, Artioli Grazia, Gladieff Laurence, O'Malley David M, Kim Jae-Weon, Garbaos Gabriel, Salutari Vanda, Caruso Giuseppe, Nicum Shibani, Bagaméri Andrea, Kesner-Hays Amanda, Bodnar Lubomir, Kang Sokbom, Vergote Ignace, Jubb Adrian M, Pashova Hristina I, Pai Sachin G, Tudor Iulia Cristina, Hopp Elizabeth, Gilbert Lucy, Mileshkin Linda, Devaux Alix, Lorusso Domenica, Kim Byoung-Gie, Lee Yong Jae, Oaknin Ana, Scaranti Mariana, Clamp Andrew, Colombo Nicoletta, McCollum Michael E, Diakos Connie, Scandurra Giuseppa, Leiser Aliza L, Balázs Boglárka, Monk Bradley J, De La Cueva Helena, McClung Emily, Kaczmarek Emilie, Slomovitz Brian, de Carvalho Calabrich Aknar Freire, Churruca Cristina, Cassani Chiara, You Benoit, Van Gorp Toon, Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial 2025
Annals of oncology Mayadev J, Dry H, Estevez-Diz M D P, Limaye S, Xin W, Kahán Z, Vera L, Rey F, Santini A, Leiva M, Vázquez Limón J C, Ramírez Godinez F J, Cetina-Pérez L D C, Wu X, Shapira-Frommer R, Galaz P, Meléndez Mier G, Mandai M, Varga S, Molina Alavez A, Alarcon-Rozas A E, Valdiviezo N, Acevedo C, Figueroa A, Monk B J, Broggi M A S, Yuan D Y, Stewart R A, Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses 2025
Journal of clinical oncology Bujnak Alyssa, Birrer Michael J., Hamilton Alina, Sill Michael, Monk Bradley J., Hari Anjali, Penson Richard T., Lankes Heather A., Hoadley Katherine A., Liu Hongwei, Szot Christopher, Ramondetta Lois M., Oaknin Ana, Leitao Mario Mendes, Copeland Larry J., Ramirez Nilsa C., Wei Lei, Tewari Krishnansu Sujata, miRNA(s) expression as predictive biomarkers in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 NIH Cancer Moonshot 43:16_suppl, p. 5523 - 5523 2025
International journal of gynecological cancer Lightfoot Michelle DS, Moore Kathleen N., Eskander Ramez N., Herzog Thomas J., Pothuri Bhavana, Rubinstein Maria M., Monk Bradley J., Lutz Kathleen, Oral Mucositis Associated with Antibody-Drug Conjugates in Gynecologic Oncology: Strategies for Prevention and Treatment, p. 101997 2025
International journal of gynecological cancer Secord Angeles Alvarez, Alvarez Ronald D., Mutch David, Randall Leslie M., Mannel Robert S., Small Michelle N., Coleman Robert L., Herzog Thomas J., Monk Bradley J., Moore Kathleen N., Copeland Larry J., Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: The GOG Foundation, Inc.’s Scholar Career Development Award and New Investigator Program, p. 101982 2025
Journal of clinical oncology Shahin Mark S., Moore Richard G., Hietanen Sakari, O’Cearbhaill Roisin E., Mangili Giorgia, Berton Dominique, Rubio-Pérez Maria Jesús, Burger Robert Allen, Braicu Elena Ioana, Monk Bradley J., Shtessel Luda, Cloven Noelle, Aaquist Haslund Charlotte, Herzog Thomas J, Lim Jonathan, Gonzalez Martin Antonio, McCormick Colleen C., Barretina-Ginesta Maria-Pilar, O’Malley David M., Honhon Brigitte, Impact of disease progression on health-related quality of life (HRQOL): Updated results from the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line (1L) maintenance therapy in patients with newly diagnosed advanced ovarian cancer (aOC) 43:16_suppl, p. 5551 - 5551 2025
Journal of clinical oncology Mayadev Jyoti, Vázquez Limón Juan Carlos, RamIrez Godinez Francisco Javier, Leiva Manuel, Alarcon-Rozas Ashley Efrain, Cetina Lucely Del Carmen, Varga Szilvia, Molina Alavez Alejandro, Valdivieso Natalia, Wu Xiaohua, Limaye Sewanti Atul, Mandai Masaki, Shapira-Frommer Ronnie, Estevez-Diz Maria Del Pilar, Xin Wenjing, Broggi Maria, Stewart Ross, Monk Bradley J., Yuan Daniel Y., Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses 43:16_suppl, p. 5502 - 5502 2025
Journal of clinical oncology Salani Ritu, Lin Zhongqiu, Lindemann Kristina, Mirza Mansoor Raza, Nishio Shin, Cáceres Valeria, Oaknin Ana, Kurtz Jean Emmanuel, Valabrega Giorgio, Harter Philipp, Van Gorp Toon, Gilbert Lucy, Sadozye Azmat, De Rêgo Barros Lilian Arruda, Boere Ingrid A., Marth Christian, Duska Linda R., Monk Bradley J., Li Xin Tong, Tekin Cumhur, , TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of physician’s choice as second-line treatment for recurrent or metastatic cervical cancer 43:16_suppl 2025
Journal of clinical oncology Mercieca-Bebber Rebecca, Lee Yeh Chen, Barnes Elizabeth H., Moore Kathleen N., Fyles Anthony, Narayan Kailash, Khaw Pearly, Buck Martin, Brooks Susan, Holschneider Christine, Lea Jayanthi Sivasothy, Stuckey Ashley, Lad Thomas E., Spirtos Nicola M., Stockler Martin R., Boyd Leslie R., Small William, Monk Bradley J., Mileshkin Linda R., King Madeleine T., Patient-reported outcomes (PROs) in locally advanced cervical cancer (LACC): Insights from the OUTBACK trial 43:16_suppl, p. 5503 - 5503 2025
ESMO open Oaknin A., Littell R., Fujiwara K., Kristeleit R., Monk B.J., Prendergast E., Salutari V., Schenker M., Martinez-Garcia J., Yeku O., Ueland F., Lee J-Y., De Vivo R., Dean A., Diaz J., Bese T., Jewell A., Van Gorp T., Maloney L., 75MO Efficacy and safety of rucaparib maintenance treatment in patients from ATHENA-MONO/GOG-3020/ENGOT-ov45 with newly diagnosed advanced ovarian cancer not associated with homologous recombination deficiency 10 2025
ESMO open Okines A., Oh D-Y., Curigliano G., Mizuno N., Rorive A., Hamilton E.P., Soliman H., Takahashi S., Bekaii-Saab T., Monk B.J., Nakamura Y., Ramos J.D., Nguyen D., O'Malley D., Reck M., Yu E., Drees A., Tan Q., Stinchcombe T., Pohlmann P.R., 304MO Tucatinib and trastuzumab for previously treated HER2-mut MBC: Final analysis of a phase II basket study (SGNTUC-019) 10, p. 104876 2025
International journal of gynecological cancer Podder Vivek, Cobb Lauren Patterson, Grisham Rachel N., Coleman Robert L., Slomovitz Brian M., Monk Bradley J., Herzog Thomas, Gershenson David M., Repurposing FDA-Approved Cancer Therapies: Exploring Endocrine and Targeted Pathways in Low-Grade Serous Ovarian Cancer Treatment, p. 101938 2025
Cancer treatment reviews Monk Bradley J., Sehouli Jalid, Lorusso Domenica, Fujiwara Keiichi, Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review, p. 102945 2025
Gynecologic oncology Matulonis Ursula A., Mahner Sven, Berton Dominique, Berek Jonathan S., Redondo Andrés, Herrstedt Jørn, Oza Amit, Lindahl Gabriel, Haslund Charlotte A., Marmé Frederik, Tinker Anna V., Ledermann Jonathan A., Benigno Benedict, Mirza Mansoor R., Bains Manjinder, González-Martín Antonio, Bécourt Stéphanie, Colombo Nicoletta, Malinowska Izabela A., Liu Wenlei, Monk Bradley J., ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety 195, p. 192 2025
Gynecologic oncology Leath, 3rd Charles A, Holman Laura L, Deng Wei, Mell Loren K, Richardson Debra L, Walker Joan L, Arend Rebecca C, Lea Jayanthi S, Amarnath Sudha R, Santos-Reyes Luis Javier, Chon Hye Sook, Mayadev Jyoti, Jegadeesh Naresh, DiSilvestro Paul, Chino Junzo P, Ghamande Sharad A, Gao Lei, Albuquerque Kevin, Quick Allison M, Donnelly Eric, Feddock Jonathan M, Lowenstein Jessica, Kunos Charles M, MacKay Helen, Aghajanian Carol, Monk Bradley J, Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial 195, p. 122 - 133 2025
Gynecologic oncology Carter Jeanne, Huang Helen Q, Monk Bradley J, Vicus Danielle L, Kim Yong-Beom, Kim Moon-Hong, Stuckey Ashley, Thawani Nitika, Holman Laura L, Fleury Aimee C, Pearson J Matthew, Feltmate Colleen, Shahin Mark, Lea Jayanthi, Robertson Sharon E, Warshal David, Backes Floor J, Wilkinson-Ryan Ivy, Covens Allan, Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278) 195, p. 50 2025
Gynecologic oncology Covens Allan, Kim Moon-Hong, DiSilvestro Paul, Monk Bradley J, Kim Yong-Beom, Huang Helen Q, Robertson Sharon E, Fleury Almee, Pearson J Matthew, Thawani Nitika, Vicus Danielle, Holman Laura L, Shahin Mark S, Lea Jayanthi S, Wilkinson-Ryan Ivy, Feltmate Colleen, Dewdney Summer, Leitao Mario M, Elsayed Ahmed G, Carter Jeanne, Backes Floor, Warshal David, Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278) 195, p. 59 2025
European journal of cancer (1990) Vergote Ignace, Thaker Premal H., Van Gorp Toon, Laenen Annouschka, Scambia Giovanni, Cibula David, Colombo Nicoletta, Lea Jayanthi, Monk Bradley J., Gonzalez-Martin Antonio, Korach Jacob, Sehouli Jalid, Heinzelmann-Schwarz Viola, Berger Regina, Buscema Joseph, Lau Susie, Mądry Radoslaw, Denys Hannelore, Pepin Jessica Thomes, Salutari Vanda, Bagaméri Andrea, Ardizzoia Antonio, Copeland Larry J., Henry Stéphanie, Cecere Sabrina Chiara, Hruda Martin, Iglesias David A., Manso Luis, Shai Ayelet, O’Malley David M., Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study, p. 115306 2025
International journal of gynecological cancer Lorusso Domenica, Pothuri Bhavana, Monk Bradley J., Barretina-Ginesta Maria-Pilar, Vergote Ignace, O’malley David M., Haslund Charlotte A., Heitz Florian, O’cearbhaill Roisin E., Abadie-Lacourtoisie Sophie, Backes Floor J., Chase Dana M., Amit Amnon, Moore Kathleen N., Malinowska Izabela A., Graybill Whitney S., Herzog Thomas J., Golembesky Amanda K., Rubio Pérez Maria-Jesús, González-Martín Antonio, Updated Patient-Reported Outcomes In The PRIMA/ENGOT-OV26/GOG-3012 Trial Of Niraparib First-Line Maintenance Therapy In Patients With Newly Diagnosed Advanced Ovarian Cancer 35:2, p. 100093 2025
Gynecologic oncology Bogani Giorgio, Lorusso Domenica, Moore Kathleen N., Ray-Coquard Isabelle, Matulonis Ursula A., Caruso Giuseppe, Ledermann Jonathan A., González-Martín Antonio, Kurtz Jean-Emmanuel, Pujade-Lauraine Eric, Scambia Giovanni, Raspagliesi Francesco, Colombo Nicoletta, Monk Bradley J., Incorporating immune checkpoint inhibitors in epithelial ovarian cancer 193, p. 30 - 40 2025
International journal of gynecological cancer Leitao Mario M., Randall Leslie M., Lim Peter C., Bixel Kristin L., Chase Dana Meredith, Quick Allison, McCormick Colleen, Black Destin, Eskander Ramez N., Martino Martin A., Walker Joan L., Copeland Larry J., Monk Bradley J., Gotlieb Walter H., LoCoco Salvatore, ROCC/GOG-3043: A randomized controlled trial of robotic versus open surgery for early-stage cervical cancer, p. 101760 2025
International journal of gynecological cancer Salani Ritu, Lindemann Kristina, Lin Zhongqiu, Valabrega Giorgio, Nishio Shin, Oaknin Ana, Kurtz Jean-Emmanuel, Cáceres M. Valeria, Harter Philipp, Van Gorp Toon, Gilbert Lucy, Sadozye Azmat H., Do Rêgo Barros Lilian Arruda, Boere Ingrid, Marth Christian, Mirza Mansoor Raza, Monk Bradley J., Li Xin Tong, Tekin Cumhur, Duska Linda, TroFuse-020/GOG-3101/ENGOT-Cx20: A Phase 3, Randomised, Active-Controlled, Open-Label, Multicentre Study Comparing Sacituzumab Tirumotecan Monotherapy Vs Treatment Of Physician’s Choice As Second-Line Treatment For Recurrent Or Metastatic Cervical Cancer 35:2, p. 100497 2025
International journal of gynecological cancer Ghamande Sharad, Prendergast Emily, Miller Rowan E., Solovyeva Ekaterina, Del Mar Gordon Santiago Maria, Kim Yong-Man, Littell Ramey, Fujiwara Keiichi, Anttila Maarit, Connor Christy, Craib Marcia, Monk Bradley J., Kristeleit Rebecca S., Turna Hande, Ruiz Nuria, Bessette Paul, Van Le Linda, Westin Shannon N., Zvaríková Mária, Eskander Ramez N., ATHENA-MONO Post-Progression Survival Data Update In Patients With Newly Diagnosed Advanced Ovarian Cancer 35:2, p. 100319 2025
International journal of gynecological cancer Lokich Elizabeth, Jørgensen Trine Lembrecht, Black Destin, Cibula David, Gilbert Lucy, Savarese Antonella, Powell Matthew A., Herbertson Rebecca, Gill Sarah E., Monk Bradley J., Nevadunsky Nicole, Cloven Noelle, Podzielinski Iwona, Myers Tashanna, Dabrowski Christine, Ring Kari L., Stevens Shadi, Willmott Lyndsay, Mirza Mansoor Raza, Time Course Of Adverse Events In Primary Advanced Or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy In The ENGOT-EN-6-NSGO/GOG-3031/RUBY Trial 35:2, p. 101722 2025
American journal of obstetrics and gynecology Levin Gabriel, Pothuri Bhavana, Monk Bradley J, Coleman Robert, Zeng Xing, Herzog Thomas, Gilbert Lucy, Bernard Laurance, Scalia Peter, Slomovitz Brian, Racial and ethnic enrollment disparities in clinical trials leading to FDA approvals for gynecologic malignancies, p. - 2025
Nature medicine Okines Alicia F C, Curigliano Giuseppe, Mizuno Nobumasa, Takahashi Shunji, Oh Do-Youn, Rorive Andree, Soliman Hatem, Hamilton Erika P, Bekaii-Saab Tanios, Burkard Mark E, Chung Ki Y, Debruyne Philip R, Fox Jenny R, Gambardella Valentina, Gil-Martin Marta, Monk Bradley J, Olawaiye Alexander B, Nakamura Yoshiaki, Nguyen Danny, O'Malley David M, Sunakawa Yu, Pothuri Bhavana, Reck Martin, Sudo Kazuki, Van Marcke Cedric, Bieda Mark, Yu Evan Y, Ramos Jorge, Tan Sherry, Stinchcombe Thomas E, Pohlmann Paula R, Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial 2025
European journal of cancer (1990) Oaknin Ana, Gotovkin Evgeniy, Monk Bradley J, Lorusso Domenica, Damian Fernanda, Chang Chih-Long, Pikiel Joanna, Goh Jeffrey C, Hasegawa Kosei, Mora Paulo, Srivastav Ratnesh, Colombo Nicoletta, Fury Matthew G, Tewari Krishnansu S, Polastro Laura, Alia Eva Maria Guerra, Makarova Yulia, Rischin Danny, Rubio Maria Jesús, Perez Javier, Seebach Frank, Yoo Suk Young, Gao Bo, Jamil Shaheda, Lowy Israel, Samouëlian Vanessa, de Melo Andreia Cristina, Kim Hee Seung, Takahashi Shunji, Ramone Daniella, Maćkowiak-Matejczyk Beata, Kim Yong Man, Lisyanskaya Alla S, Mathias Melissa, Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial 216, p. 115146 2025
Nature reviews. Clinical oncology Francoeur Alex A, Tewari Krishnansu S, Monk Bradley J, Treatment advances across the cervical cancer spectrum 2025
Mirza Mansoor R, Chase Dana M, Slomovitz Brian M, Gilbert Lucy, Coleman Robert L, Powell Matthew A, Christensen René de Pont, Novák Zoltán, Black Destin, Sharma Sudarshan, Valabrega Giorgio, Landrum Lisa M, Hanker Lars C, Stuckey Ashley, Boere Ingrid, Gold Michael A, Auranen Annika, Raspagliesi Francesco, Pothuri Bhavana, Cibula David, McCourt Carolyn, Shahin Mark S, Gill Sarah E, Monk Bradley J, Stevens Shadi, Copeland Larry J, Tian Min, He Zangdong, Buscema Joseph, Herzog Thomas J, Zografos Eleftherios, A Plain Language Summary of “Dostarlimab for primary advanced or recurrent endometrial cancer” 2025
Journal of comparative effectiveness research Graybill Whitney S, Heitz Florian, Willmott Lyndsay J, Bruchim Ilan, Zhuo Ying, Pothuri Bhavana, Anttila Maarit, O'Malley David M, Lorusso Domenica, Estévez-García Purificación, Monk Bradley J, Denys Hannelore, Knudsen Anja, Tinker Anna V, Haggerty Ashley F, Fabbro Michel, Chan John K, Vergote Ignace, Sánchez Luis Manso, Provencher Diane, Barretina-Ginesta Maria Pilar, Hartman John, Booth Donna V, González-Martín Antonio, Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer 14:1, p. e240133 2025
J Comp Eff Res Graybill Whitney S, Vergote Ignace, Pothuri Bhavana, Anttila Maarit, O'Malley David M, Lorusso Domenica, Haggerty Ashley F, Fabbro Michel, Chan John K, Heitz Florian, Willmott Lyndsay J, Bruchim Ilan, Zhuo Ying, Sánchez Luis Manso, Provencher Diane, Estévez-García Purificación, Monk Bradley J, Denys Hannelore, Knudsen Anja, Tinker Anna V, Barretina-Ginesta Maria Pilar, Hartman John, Booth Donna V, González-Martín Antonio, Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer 14:1, p. e240133 2025
Journal of gynecologic oncology Kim Yong-Man, Tewari Krishnansu S., Hasegawa Kosei, Dubot Coraline, Cáceres M. Valeria, Lorusso Domenica, Kim Se Ik, Lee Jeong-Won, Liou Wen-Shiung, Li Kan, Nishio Shin, Tekin Cumhur, Colombo Nicoletta, Monk Bradley J., Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis 36 2025
Annals of oncology González-Martín A, Malinowska I A, Monk B J, Reply to Letter to the Editor 'Long-term outcomes in the PRIMA trial: a closer look at PFS and OS' by Wu et al 2024
Cancer research communications Zhang Hailei, Mirza Mansoor R, Monk Bradley J, Vergote Ignace, Graybill Whitney A Spannuth, Goessel Carsten, Barbash Olena, Bergamini Giovanna, Pothuri Bhavana, Feng Bin, González-Martín Antonio, Rutkowska Anna, Potential synergistic effect between niraparib and statins in ovarian cancer clinical trials 2024
Cancer Res Commun Zhang Hailei, Monk Bradley J, Rutkowska Anna, González-Martín Antonio, Mirza Mansoor R, Vergote Ignace, Pothuri Bhavana, Graybill Whitney A. Spannuth, Goessel Carsten, Barbash Olena, Bergamini Giovanna, Feng Bin, Potential synergistic effect between niraparib and statins in ovarian cancer clinical trials 2024
Oncology and therapy Monk Bradley J., Tekin Cumhur, Keefe Steve, Monberg Matthew, Muston Dominic, Boer Jennifer, van Mens Sophie, Hale Oliver, van Hees Frank, Swami Shilpi, Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States 2024
Gynecologic oncology Grisham Rachel, Lustgarten Stephanie, Thaker Premal, Oza Amit, Colombo Nicoletta, Denis Louis, O'Malley David, Banerjee Susana, Monk Bradley, Nieuwenhuysen Els, Moore Kathleen, Fabbro Michel, Oaknin Ana, A phase III, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of therapy among patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-OV81/NCRI/RAMP 301 190, p. S282 - S283 2024
Gynecologic oncology Banerjee Susana, Moore Kathleen, Clamp Andrew, Ray-Coquard Isabelle, Chon Hye Sook, Salinas Erin, Monk Bradley, Rose Peter, O'Malley David, Oaknin Ana, Holloway Robert, Gennigens Christine, Moroney John, Van Gorp Toon, Kalbacher Elsa, Newman Gregg, Van Nieuwenhuysen Els, Colombo Nicoletta, Wojtynek Nicholas, Lustgarten Stephanie, Grisham Rachel, Santin Alessandro, Ring Kari, Thaker Premal, Prendergast Emily, Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: A subgroup analysis of ENGOT-OV60/GOG-3052/RAMP 201 Part A 190, p. S55 - S56 2024
Gynecologic oncology Moore Kathleen, Williams Dennis, Musa Fernanda, Nathenson Michael, Sauer Amy, Jolliffe Darren, Rosenberg Marisa, Norry Elliot, Monk Bradley, Ray-Coquard Isabelle, Oaknin Ana, Coleman Robert, Rose Peter, Herzog Thomas, O'Malley David, Lheureux Stephanie, Morris Robert, Starks David, Lanneau Grainger, GOG-3084: A phase II trial of ADP-A2M4CD8 TCR-T cell therapy, alone or in combination with nivolumab, among patients with recurrent ovarian cancers 190, p. S281 - S282 2024
Gynecologic oncology Graybill Whitney, Haggerty Ashley, Fabbro Michel, Chan John, Heitz Florian, Willmott Lyndsay, Bruchim Ilan, Zhuo Ying, Estévez-García Purificación, Monk Bradley, Denys Hannelore, Vergote Ignace, Pothuri Bhavana, Anttila Maarit, O'Malley David, Lorusso Domenica, Knudsen Anja, Tinker Anna, Sánchez Luis Manso, Provencher Diane, Barretina-Ginesta M. Pilar, Hartman John, Booth Donna, González-Martín Antonio, Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer 190, p. S274 - S275 2024
Gynecologic oncology Pothuri Bhavana, Oaknin Ana, Monk Bradley, Graybill Whitney, Sánchez Ana Beatriz, Levy Tally, York Whitney, Malinowska Izabela, González-Martín Antonio, Denys Hannelore, McCormick Colleen, Baurain Jean-François, Tinker Anna, O'Cearbhaill Roisin, de La Motte Rouge Thibault, Hietanen Sakari, Moore Richard, Knudsen Anja, Heitz Florian, Valabrega Giorgio, Examining health-related quality of life outcomes among older patients with advanced ovarian cancer treated with niraparib first-line maintenance therapy in context with efficacy and safety findings: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial 190, p. S295 - S296 2024
Gynecologic oncology Hunsberger Kyra, Tewari Krishnansu, Randall Leslie, Chase Dana, Monk Bradley, Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis 190, p. S421 - S421 2024
Gynecologic oncology Kristeleit Rebecca, Miller Rowan, Monk Bradley, O'Malley David, Lim Myong Cheol, Coleman Robert, Herzog Thomas, Wilson Michelle, De Vivo Rocco, Oaknin Ana, Chudecka-Glaz Anita, Oza Amit, Mikheeva Olga, Buscema Joseph, Van Le Linda, Morris Robert, Van Gorp Toon, Moore Kathleen, Zagouri Flora, Shih Danny, Rob Lukáš, Craib Marcia, Connor Christy, Fujiwara Keiichi, Interim post-progression data and updated survival in patients with newly diagnosed advanced ovarian cancer in ATHENA-MONO 190, p. S10 - S11 2024
Gynecologic oncology Banerjee Susana, Roxburgh Patricia, Marsolini Diane, Westin Shannon, Eskander Ramez, Sardone Megan, Ray-Coquard Isabelle, Moore Kathleen, Berton Dominique, Monk Bradley, Van Nieuwenhuysen Els, O'Malley David, Oaknin Ana, Barlin Joyce, Anderson Charles, Redondo Andrés, Brubaker Lindsay, Ang Joo Ern, Cloven Noelle, Baurain Jean-François, A phase Ib, multicenter, open-label study of NXP800, a novel GCN2 kinase activator, among patients with platinum-resistant, ARID1A-mutated ovarian cancer (ENGOT-GYN5/NCRI/NXP800-101; GOG-3087) 190, p. S302 - S302 2024
Annals of oncology Lorusso D, Colombo N, Dubot C, Cáceres M V, Hasegawa K, Gümüş M, Shapira-Frommer R, Salman P, Yañez E, Olivera M, Toker S, Castonguay V, Arkhipov A, Li K, Samouëlian V, Tekin C, Tewari K S, Monk B J, Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study 2024
International journal of gynecological cancer Barlin Joyce, Hand Lauren, Black Destin, Cottrill Hope, Eshed Helen, Durbin Joan, O’Malley David, Chuang Linus, Chisamore Michael, Zheng Pan, Lim Peter, Pepin Jessica Thomes, Hopp Elizabeth, Cloven Noelle, Monk Bradley, Liu Yang, Shpyro Svetlana, LB010/#1590 A phase 2 randomized dose optimization trial of gotistobart, a PH-sensitive anti-CTLA-4, in combination with pembrolizumab in platinum-resistant ovarian cancer (PROC, preserve-004/GOG-3081; NCT05446298) 34, p. A6 - A8 2024
International journal of gynecological cancer Lorusso Domenica, Van Gorp Toon, Zagouri Flora, Bodnar Lubomir, Collins Dearbhaile, Korach Jacob, Marth Christian, Kroep Judith, Zhu Jianqing, Hasegawa Kosei, Samouëlian Vanessa, Lee Jung-Yun, Casarotto Fernanda, Antill Yoland, Chase Dana, Shahin Mark, Orlowski Robert, Woodhouse Kristina, Cui Yi, Willmott Lyndsay, Monk Bradley, TP003/#1538 Phase 3 ENGOT-en23/GOG-3095/MK-2870–005 study: sacituzumab tirumotecan (Sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who received prior chemotherapy and immunotherapy 34, p. A348 - A348 2024
International journal of gynecological cancer Grisham Rachel, O’Malley David, Monk Bradley, Van Nieuwenhuysen Els, Moore Kathleen, Fabbro Michel, Colombo Nicoletta, Oaknin Ana, Thaker Premal, Oza Amit, Lustgarten Stephanie, Youssoufian Hagop, Banerjee Susana, PR029/#943 A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of therapy in patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-ov81/NCRI/RAMP 301 34, p. A53 - A54 2024
International journal of gynecological cancer Bixel Kristin, Lee Sun Joo, Baiocchi Glauco, Black Destin, Eskander Ramez, Gotlieb Walter, Lococo Salvatore, Randall Leslie, Martino Martin, Mccormick Colleen, Monk Bradley, Quick Allison, Walker Joan, Leitao Mario, Chase Dana, TP001/#1584 GOG-3043 (nct04831580): a randomized non-inferiority trial of robotic versus open surgery for early stage cervical cancer (ROCC) 34, p. A347 - A347 2024
International journal of gynecological cancer Oaknin Ana, Lorusso Domenica, Lee Jung-Yun, Pietzner Klaus, Auranen Annika, Cibula David, Lee Yeh Chen, Schilder Russell, Gao Bo, Salutari Vanda, Tan David, Oza Amit, Miller Rowan, Pothuri Bhavana, Tasca Giulia, O’Malley David, Monk Bradley, Wendel Naumann R., Lu Lin, Berman Craig, Borgman Anne, TP010/#1537 Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: the reframe-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study 34, p. A351 - A351 2024
International journal of gynecological cancer Banerjee Susana, Youssoufian Hagop, Kalbacher Elsa, Van Gorp Toon, Lustgarten Stephanie, Van Nieuwenhuysen Els, Grisham Rachel, Aghajanian Carol, Santin Alessandro, Ring Kari, Colombo Nicoletta, Chon Hye Sook, Thaker Premal, Prendergast Emily, Moore Kathleen, Cortés-Salgado Alfonso, Clamp Andrew, O’malley David, Monk Bradley, Fabbro Michel, LB007/#1548 Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201 34, p. A13 - A13 2024
European journal of cancer (1990) Nakamura Y., Monk B.J., Bekaii-Saab T., Hayashi H., Mizuno N., Nguyen D., Hamilton E., Okines A., O’Malley D.M., Pohlmann P.R., Pothuri B., Reck M., Sudo K., Drees A., Sunakawa Y., Takahashi S., Yu E.Y., Tan S., Stinchcombe T.E., 3 Oral: Tucatinib and Trastuzumab for Patients With Previously Treated, HER2- Altered Solid Tumors (SGNTUC-019): A Phase 2 Basket Study 211, p. 114532 2024
Annals of oncology Monk B.J., Vergote I., Shahin M.S., González-Martín A., Graybill W., Mirza M.R., McCormick C.C., Lorusso D., Heitz F., Moore R.G., Freyer G., O’Cearbhaill R.E., O’Malley D.M., Redondo A., Vulsteke C., Chase D.M., Barretina-Ginesta M.P., Pothuri B., Bradley W.H., Haslund C.A., Pisano C., DiSilvestro P., Gaba L., Holman L.L., Pérez M. J. Rubio, Shtessel L., Herzog T.J., Bruchim I., Compton N., Malinowska I.A., Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial 2024
International journal of gynecological cancer Vergote Ignace, Valabrega Giorgio, Monk Bradley J, Herzog Thomas, Perez Fidalgo Alejandro, Antill Yoland, Colombo Nicoletta, Cibula David, Pothuri Bhavana, Sehouli Jalid, Korach Jacob, Barlin Joyce, Papadimitriou Christos A, van Gorp Toon, Richardson Debra, McCarthy Michael, Mirza Mansoor Raza, Li Kai, Kalyanapu Pratheek, Slomovitz Brian, Coleman Robert L, ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: ratio 34:8, p. 1283 2024
ESMO open Kristeleit R., O'Malley D., Lim M-C., McNeish I., Coleman R.L., Monk B.J., Herzog T.J., Wilson M., Fehm T.N., Van Gorp T., Lisyanskaya A.S., Oza A.M., Mikheeva O., Buscema J., Lindahl G., Shih D., Gao B., Lorusso D., Morgan M., Fujiwara K., 49MO Updated progression-free survival (PFS) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) treated with rucaparib (RUC) in ATHENA-MONO 9, p. 103556 2024
Gynecologic oncology Pothuri Bhavana, Van Le Linda, Burger Robert A., Gaba Lydia, Guerra Eva, Bender David, Baurain Jean-François, Korach Jacob, Cloven Noelle, Churruca Cristina, Follana Philippe, DiSilvestro Paul, Bacqué Emeline, Jardon Kris, Pisano Carmela, Peen Ulla, Mäenpää Johanna, Gupta Divya, Li Yong, Compton Natalie, Antonova Jenya, Monk Bradley J., González-Martín Antonio, Heitz Florian, Han Sileny, Chase Dana M., Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial 184, p. 168 - 177 2024
Chan John, Richardson Michael, Tian Chunqiao, Monk Bradley, McNally Leah, Kesterson Joshua, Lin Ken, Darcy Kathleen, Kapp Daniel, Landrum Lisa, Copeland Larry, Berry Laurel, Bell Jeffery, Spirtos Nick, Walker Joan, Wenham Robert, Phippen Neil, Tewari Krishnansu, Shahin Mark, Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study 2024
Gynecologic oncology reports Rimel Bobbie J., Wang Travis, Chase Dana M., Perhanidis Jessica, Ghazarian Armen A., Du Ella Xiaoyan, Monk Bradley J., Salani Ritu, Song Jinlin, Golembesky Amanda K., Hurteau Jean A., Kalilani Linda, Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance set, p. 101332 2024
Gynecologic oncology Valabrega Giorgio, Pothuri Bhavana, Oaknin Ana, Graybill Whitney S, Sánchez Ana Beatriz, McCormick Colleen, Baurain Jean-François, Tinker Anna V, Denys Hannelore, O'Cearbhaill Roisin E, Hietanen Sakari, Moore Richard G, Knudsen Anja Ør, de La Motte Rouge Thibault, Heitz Florian, Levy Tally, York Whitney, Gupta Divya, Monk Bradley J, González-Martín Antonio, Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial 2024
The New England journal of medicine Mirza Mansoor R, Slomovitz Brian M, Chase Dana M, dePont Christensen René, Novák Zoltán, Valabrega Giorgio, Black Destin, Gilbert Lucy, Sharma Sudarshan, Landrum Lisa M, Hanker Lars C, Stuckey Ashley, Pothuri Bhavana, Boere Ingrid, Gold Michael A, Auranen Annika, Cibula David, McCourt Carolyn, Raspagliesi Francesco, Buscema Joseph, Shahin Mark S, Gill Sarah E, Monk Bradley J, Herzog Thomas J, Copeland Larry J, Tian Min, Coleman Robert L, He Zangdong, Stevens Shadi, Zografos Eleftherios, Powell Matthew A, , Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer, p. - 2023
Gynecologic oncology Chase Dana M., Romeo Marin Margarita, Backes Floor, Han Sileny, Graybill Whitney, Mirza Mansoor Raza, Pothuri Bhavana, Mangili Giorgia, O'Malley David M., Berton Dominique, Willmott Lyndsay, Baumann Klaus, Coleman Robert L., Safra Tamar, Heinzelmann-Schwarz Viola, Lorusso Domenica, Karl Florian M., Woodward Tatia, Monk Bradley J., Gonzalez-Martin Antonio, , Impact of disease progression on health-related quality of life of advanced ovarian cancer patients - Pooled analysis from the PRIMA trial 166:3, p. 494 - 502 2022
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY Barretina-Ginesta Maria-Pilar, Chase Dana M, Lorusso Domenica, Gupta Divya, Monk Bradley J, Auranen Annika, Han Sileny, Pothuri Bhavana, Braicu Elena, Amit Amnon, Redondo Andres, Shah Ruchit, Kebede Nehemiah, Hawkes Carol, Woodward Tatia, O'Malley David M, Gonzalez-Martin Antonio, Anderson Charles, Abadie-Lacourtoisie Sophie, Cloven Noelle, Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial 14 2022
Journal of clinical oncology Bixel Kristin Leigh, Chase Dana Meredith, Leitao Mario M., Gotlieb Walter H., Quick Allison, Lim Peter C, Eskander Ramez Nassef, LoCoco Salvatore, Walker Joan L., Martino Martin A, McCormick Colleen, Myers Tashanna K. N., Tewari Krishnansu Sujata, Slomovitz Brian M., Randall Leslie M., Copeland Larry J., Monk Bradley J., ROCC/GOG-3043: A randomized non-inferiority trial of robotic versus open radical hysterectomy for early-stage cervical cancer 40:16_suppl, p. TPS5605 - TPS5605 2022
International journal of gynecological cancer Mäenpää Johanna, Pothuri Bhavana, Follana Philippe, Han Sileny, Chase Dana, Bender David, Bacque Emeline, Yong L I, González-Martin Antonio, Monk Bradley J, 294 Patient-reported outcomes (PROS) in patients (PTS) receiving niraparib in the prima/engot-ov26/gog-3012 trial 30:Suppl 4, p. A63 - A64 2020
International journal of gynecological cancer Freyer G, Monk B, Pothuri B, Han S, Chase D, Heitz F, Guerra E, Burger R, Gaba L, Van Le L, Peen U, Bender D, Korach J, Baurain J F, Jardon K, Pisano C, Maenpaa J, González-Martín A, Bacque E, Li Y, Eliason L, DiSilvestro P, Cloven N, Churruca C, Follana P, Hoskins P, 17 Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial 30:Suppl 3, p. A12 - A13 2020
Gynecologic oncology Eakin Cortney M., Monk Bradley J., Norton Taylor J., Chase Dana M., Management of nausea and vomiting frompoly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer 159:2, p. 581 - 587 2020
Heitz F, Cloven N, Monk B J, Gaba L, Van Le L, Guerra E, Bender D, Korach J, Follana P, Maenpaa J, Baurain J F, Pisano C, Peen U, Bacque E, Li Y, Burger R, González-Martin A, Pothuri B, Han S, Chase D, Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial 2020
Annals of oncology Pothuri B., Gaba L., Han S., Chase D., Heitz F., Burger R., Van Le L., Cloven N.G., Guerra E., Bender D., Korach J., Follana P., Maenpaa J., Baurain J-F., Pisano C., Peen U., Bacqué E., Li Y., Martín A. González, Monk B.J., 810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial 31, p. S612 - S613 2020
International journal of gynecological cancer Chase Dana, Pulaski Heather L, Leitao Mario, Oaknin Ana, Huh Warner K, Robison Katina, Sill Michael W, Guntupalli Saketh R, Richardson Debra, Salani Ritu, Wenzel Lari B, Gil Karen, Tewari Krishnansu Sujata, Huang Helen Q, Monk Bradley J, Ramondetta Lois Michelle, Penson Richard T, Landrum Lisa M, Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study 30:5, p. 596 - 601 2020
Gynecologic oncology Eakin C., Monk B., Chase D., Ewongwo A., A Qualitative Evaluation of Clinical Burden of Poly (ADP-ribose) Polymerase Inhibitor Usage in a Community Oncology Practice 156:3, p. e23 - e24 2020
Scientific reports Łaniewski Paweł, Monk Bradley J., Greenspan David L., Cui Haiyan, Roe Denise J., Barnes Dominique, Goulder Alison, Chase Dana M., Herbst-Kralovetz Melissa M., Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis 9:1, p. 7333 - 7333 2019
Gynecologic oncology Liang J., Stone J., Monk B.J., Wolsiefer K., Chase D.M., Evidence of provider implicit bias toward women with cervical cancer: A study of physicians and nurses caring for gynecologic oncology patients 149, p. 137 - 137 2018
Journal of clinical oncology Tewari Krishnansu Sujata, Feng Minjie, Lheureux Stephanie, Vergote Ignace, Oaknin Ana, Alvarez Edwin, Chase Dana Meredith, Gaillard Stephanie, Rischin Danny, Santin Alessandro, Fury Matthew G., Lowy Israel, Mathias Melissa, Monk Bradley J., GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer 36:15_suppl, p. TPS5600 - TPS5600 2018
Gynecologic oncology Moreno A., Vo Elise, Bhattarai B., Patel S., Farley J., Willmott L., Monk B., Chase D., Factors Associated with Increased Narcotic Usage after Undergoing Robotic Assisted Laparoscopy 147:1, p. 203 - 203 2017
Gynecologic oncology Barnes Dominique, Monk Bradley J., Chase Dana, Shields Kristin M., Willmott Lyndsay J., Farley John, Patient characteristics associated with obesity in an endometrial cancer patient: first steps towards the design of a weight loss intervention 147:1, p. 215 - 215 2017
Gynecologic oncology Barnes Dominique, Willmott Lyndsay J., Farley John, Monk Bradley J., Chase Dana, Clinic-based Depression Screening in Gynecologic Oncology Patients using the Patient Health Questionnaires-2 (PHQ-2): are we identifying the highest risk patients? 147:1, p. 215 - 215 2017
Gynecologic Oncology Chase Dana M., Monk Bradley J., Chaplin D. J., The Development and use of Vascular Targeted Therapy in Ovarian Cancer 145:2, p. 393 - 406 2017
Gynecologic oncology research and practice Minion Lindsey E., Chase Dana M., Farley John H., Willmott Lyndsay J., Monk Bradley J., Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study 3:1, p. 4 - 4 2016
Obstetrics and gynecology (New York. 1953) Chase Dana M, Craig Christine D, Fedewa Stacey A, Virgo Katherine S, Farley John H, Halpern Michael, Monk Bradley J, Lin Chun Chieh, Disparities in Vulvar Cancer Reported by the National Cancer Database: Influence of Sociodemographic Factors 126:4, p. 792 - 802 2015
Gynecologic oncology Shields K., Baxter L., Renda L., Pipe J., Craig C., Monk B., Chase D., Abstract 15: Cancer-related fatigue in gynecologic oncology patients undergoing chemotherapy 137:3, p. 596 - 596 2015
Gynecologic oncology Shields K.M., Willmott L., Farley J.H., Monk B.J., Chase D., Factors associated with low educational background in uterine cancer patients 137, p. 123 - 123 2015
Gynecologic oncology Chase Dana M., Wenzel Lari B., Huang Helen, Foss Cassandra D., Monk Bradley J., Burger Robert A., Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: Characteristics associated with toxicity and the effect of substitution with docetaxel: An NRG Oncology/Gynecologic Oncology Group study 136:2, p. 323 - 327 2015
Gynecologic Oncology Osann K., Wenzel L., Hsieh S., Monk Bradley J., Chase D., Cella D., Nelson E. L., Factors associated with poor quality of life among cervical cancer survivors: implications for clinical care and clinical trials 135:2, p. 266 - 272 2014
Gynecologic oncology research and practice Foss Cassandra D, Farley John H, Dalton Heather J, Monk Bradley J, Chase Dana M, Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways 1:1, p. 4 - 4 2014
International Journal of Gynecological Cancer Liang Winnie S., Nasser Sara, Aldrich Jessica, Kurdoglu Ahmet, McDonald Jacquelyn, Izatt Tyler, Christoforides Alexis, Baker Angela, Craig Christine, Egan Jan B., Chase Dana M., . . . Monk, Bradley J., Monk Bradley J., Phillips Lori, Reiman Rebecca, Simultaneous characterization of somatic events and HPV-18 integration in a metastatic cervical carcinoma patient using DNA and RNA sequencing 24:2, p. 329 - 338 2014
Gynecologic oncology Craig C., Gibson S.J., Osann K.E., Farley J., Willmott L., Monk B.J., Chase D.M., The characteristics and associations of pelvic pain in gynecologic cancer patients: A single institution study 131:1, p. 264 - 264 2013
Gynecologic oncology Craig C., Gibson S., Osann K., Farley J., Monk B., Chase D., Pelvic pain, quality of life (QOL), and exercise in gynecologic cancer patients: A single institution study 130:1, p. e31 - e32 2013
Gynecologic oncology Craig C., Lin C., Fedewa S., Virgo K., Farley J., Monk B., Chase D., Therapeutic choices and outcomes in vulvar cancer cases reported by the National Cancer Database Registry 130:1, p. e163 - e163 2013
Critical Reviews in Oncology/Hematology Monk Bradley J., Dalton Heather, Farley John H., Chase Dana M., Benjamin Ivor, Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer 86:2, p. 161 - 175 2013
European Journal of Gynaecological Oncology Jordan S. M., Rutgers J. K., Chase D. M., Watanabe T., Osann K., Monk Bradley J., High pathologic misdiagnosis of cervical adenocarcinoma in situ 34:5, p. 446 - 449 2013
Gynecologic Oncology Chase Dana M., Chambers Mark D., Sill Michael W., Monk Bradley J., Darcy Kathleen M., Han Ernest S., Buening Barbara J., Sorosky Joel I., Fruehauf John P., Burger Robert A., Changes in Tumor Blood Flow as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) May Predict Activity of Single Agent Bevacizumab in Recurrent Epithelial Ovarian (EOC) and Primary Peritoneal Cancer (PPC) Patients: An exploratory a 126:3, p. 375 - 380 2012
Expert review of pharmacoeconomics & outcomes research Chase Dana M., Wenzel L. B., Monk Bradley J., Quality-of-life results used to endorse changes in standard of care for recurrent platinum-sensitive ovarian cancer 12:3, p. 279 - 281 2012
Gynecologic oncology Osann Kathryn, Wenzel Lari, Sappington Sandra, Dogan Aysun, Hsieh Susie, Chase Dana M., Monk Bradley J., Nelson Edward L., Recruitment and retention results for a population-based cervical cancer biobehavioral clinical trial 121:3, p. 558 - 564 2011
Gynecologic oncology Chase D., Chambers M., Sill M., Darcy K., Buening B., Han E., Fruehauf J., Monk B., Sorosky J., Burger R., Changes in tumor blood flow as estimated by dynamic-contrast MRI may predict activity of single-agent bevacizumab in recurrent epithelial ovarian cancer and primary peritoneal cancer: An exploratory analysis of a Gynecologic Oncology Group phase II trial 120, p. S65 - S66 2011
Future oncology (London, England) Chase Dana M., Watanabe Tawny, Monk Bradley J., Assessment and significance of quality of life in women with gynecologic cancer 6:8, p. 1279 - 1287 2010
Expert review of anticancer therapy Chase Dana M., Tewari Krishnansu S., Monk Bradley J., Wenzel Lari B., Supportive care for women with gynecologic cancers 8:2, p. 227 - 241 2008